ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
4 registry-linked trialsAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 293 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
293citing papers in PubMed, 7 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
NCT05677113 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation
A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC
Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study
Who cites it
293 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.Journal for immunotherapy of cancer · 2023Guideline
- Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review.Journal for immunotherapy of cancer · 2023Pooled it
- Deciphering radiological stable disease to immune checkpoint inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Pooled it
- Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Cancer research communications · 2026Trial
- Trial
- Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432).Signal transduction and targeted therapy · 2024Trial
- Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.Nature communications · 2024Trial
- Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy.Nature communications · 2024Trial
- SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.Signal transduction and targeted therapy · 2024Trial
- Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.Nature communications · 2024Trial
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.Cancer discovery · 2023Trial
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.Nature medicine · 2023Trial
- Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.Molecular oncology · 2023Trial
- Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.Journal for immunotherapy of cancer · 2022Trial
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.Nature medicine · 2022Trial
233 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Sarah B Goldberg *Department of Medicine (Medical Oncology), Yale School of Medicine, Yale University, New Haven, Connecticut.
Azeet Narayan *Department of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Adam J Kole *Department of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Roy H DeckerDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Jimmitti TeysirDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Nicholas J CarrieroSimons Foundation, New York, New York.
Angela LeeDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Roxanne NematiDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Sameer K NathDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Shrikant M ManeDepartment of Genetics, Yale School of Medicine, Yale University, New Haven, Connecticut.
Yanhong DengYale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut.
Nitin SukumarYale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut.
Daniel ZeltermanDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
Daniel J BoffaDepartment of Thoracic Surgery, Yale School of Medicine, Yale University, New Haven, Connecticut.
Katerina PolitiDepartment of Pathology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Scott N GettingerDepartment of Medicine (Medical Oncology), Yale School of Medicine, Yale University, New Haven, Connecticut.
Lynn D WilsonDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Roy S HerbstDepartment of Medicine (Medical Oncology), Yale School of Medicine, Yale University, New Haven, Connecticut.
Abhijit A PatelDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut. abhijit.patel@yale.edu.
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1MCirculating DNA as a Marker of Treatment Efficacy and Failure in Lung CancerR01CA197486 · NCI · YALE UNIVERSITY · PI PATEL, ABHIJIT · 2016 to 2020
$1.9MHigh Performance Computing Instrumentation for the Yale Center for Genome AnalysiS10OD018521 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2015 to 2015
$890kNCATS NIH HHS UL1 TR001863NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA197486NIH HHS S10 OD018521
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorCirculating Tumor DNAAntineoplastic Agents, ImmunologicalB7-H1 AntigenDisease ProgressionHumansImmunotherapyLung NeoplasmsMutationPrognosisProgrammed Cell Death 1 ReceptorSurvival AnalysisTime FactorsTomography, X-Ray ComputedTreatment OutcomeAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCirculating Tumor DNAPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03694262ClinicalTrials.gov
NCT05677113ClinicalTrials.gov
NCT05715229ClinicalTrials.gov
NCT06105177ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.